!!! New Study Publication!!!
"Active Chest Tube Clearance Added to an Enhanced Recovery After Cardiac Surgery (ERAS) Program Improves Outcomes and Reduces Resource Utilization"


Adding PleuraFlow’s Active Chest Tube Clearance (ATC) to an ERAS cardiac surgery program reduced Retained Blood Syndrome by 41%, postoperative atrial fibrillation (POAF) by 17%, and ICU time by 30% in 684 patients compared to 650 controls, improving outcomes and resource utilization. (Gerdisch, et al, 2025)

The PleuraFlow ACT System:
Indications for Use

The PleuraFlow® System is indicated for use during cardiothoracic surgical procedures and chest trauma. Its Active Clearance Technology proactively removes clots formed inside the chest tube to prevent or minimize chest tube occlusion with clot. A patent chest tube enables evacuation of blood and fluid from the operative site after closure of the surgical wound and reduces retained blood.

In the United States the product is indicated for adult and pediatric patients including infant, preadolescent and adolescent patients under clinical settings.

In the European Community the product is indicated for adult and pediatric patients including infants ranging in age from six months old to 18 years old under clinical settings.